Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 245-904-8 | CAS number: 23843-64-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
Toxicity to reproduction (fertility): no data available
Effect on fertility: via oral route
- Endpoint conclusion:
- no study available
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
Toxicity to reproduction (fertility)
According to Regulation (EC) No 1907/2006, Annex VIII 8.7.1. Column 2, a screening study for reproductive/developmental toxicity for assessment of reproductive toxicity is not required if a pre-natal developmental toxicity study (Annex IX, 8.7.2) or an Extended One-Generation Reproductive Toxicity Study (Annex IX, Section 8.7.3) is available. A GLP compliant pre-natal developmental toxicity study (rat, oral route) with the source substance (structural analogue or surrogate) ureidopropyltrialkoxysilane, mixed methoxy and ethoxy esters (CAS 116912-64-2) is available and has been used as read-across. The read-across is conducted based on an analogue approach, in accordance with the Regulation (EC) 1907/2006 to avoid tests in terms of animal welfare. Details on read across justifications can be found in the attached justification in the respective target entry and in the overall justification for grouping of substances attached in IUCLID Section 13.
Effects on developmental toxicity
Description of key information
Prenatal developmental toxicity study (OECD TG 414, GLP): NOAEL=1000 mg/kg/bw/day (highest dose tested) (RA from CAS 116912-64-2)
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- Please refer to the attached justification below and the overall justification for grouping of substances attached in IUCLID Section 13.
- Reason / purpose for cross-reference:
- read-across: supporting information
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- other: no adverse clinical signs, no treatment-related effect on body weight, food consumption, prenatal data parameters and gross pathology
- Key result
- Abnormalities:
- no effects observed
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no treatment-related and toxicologically relevant effect on litter weight data, external, skeletal, visceral or craniofacial foetal findings
- Key result
- Abnormalities:
- no effects observed
- Key result
- Developmental effects observed:
- no
Reference
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- The study was conducted according to an appropriate OECD test guideline and in compliance with GLP.
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
No data on repeated dose toxicity on 1-[3-(trimethoxysilyl)propyl]urea (CAS 23843-64-3) are available. Therefore, the risk assessment was performed based on the available data from the source substance ureidopropyltrialkoxysilane, mixed methoxy and ethoxy esters (CAS 116912-64-2). The source substance is the reaction mass of 1-[3-(trimethoxysilyl)propyl]urea, 1-[3-(dimethoxyethoxysilyl)propyl]urea, 1-[3-(methoxydiethoxysilyl)propyl]urea and 1-[3-(triethoxysilyl)propyl]urea and therefore contains the target substance as one of its components. In accordance with Regulation (EC) No. 1907/2006 Annex XI, 1.5 “Grouping of substances and read across” and in accordance with the Read across assessment framework (RAAF, ECHA 2017) read across from the analogue substance has been applied to support the human health hazard assessment of 1-[3-(trimethoxysilyl)propyl]urea (CAS 23843-64-3).
Details on read across justifications can be found in the attached justification in the respective target entry and in the overall justification for grouping of substances attached in IUCLID Section 13.
In an OECD 414 study conducted in accordance to GLP, nulliparous and non-pregnant females were mated with males (2:1 ratio) and divided into four groups based on their body weights on the day of sperm positive vaginal smears (GD 0) (BSL, 2021). The test item ureidopropyltrialkoxysilane, mixed methoxy and ethoxy esters (CAS 116912-64-2) was administered via gavage during gestation days 5 to 19 at dose levels of 100, 300 and 1000 mg/kg bw/day. The control group received sterile water. The 4 groups comprised 25 female Wistar rats each.
In dams, no mortality occurred during the treatment period of this
study and all animals survived until terminal sacrifice. Additionally,
there were no clinical signs of toxicological relevance observed in any
of the treatment groups. The mean body weight remained unaffected and
increased during the progress of the study in the control and treatment
groups. There was no effect on body weight gain (gestation day 0-20)
observed in any of the treatment groups when compared to the controls.
In correlation to the body weight and body weight gain, food consumption
in the treatment groups was comparable to the controls. There was no
statistically significant effect observed on food consumption in
treatment groups throughout the study period when compared with the
controls.
No test item-related effects of toxicological relevance or
statistical significance were noted for any of prenatal data parameters
like terminal body weight, gravid uterus weight, adjusted maternal
weights, number of corpora lutea, implantation sites, live foetuses,
early and late resorptions, number of male and female foetuses, sex
ratio, number of foetuses in each uterine horn and percent pre- and
post-implantation loss. No dead foetuses were noted in any of the
groups. Successful mating resulted in 24/25 pregnancies in the mid- and
high-dose groups compared to 25/25 pregnancies in the control and
low-dose group. No gross pathological changes of toxicological relevance
were observed during the macroscopic examination of the treated females.
There were no test item-related effects of toxicological relevance or statistical significance observed for any litter data parameters like mean foetus weight (individual and litter basis), male and female foetus weight (individual basis), the total, male and female litter weight (litter basis) in any of the treatment groups when compared with the controls. All group mean values and individual values for various litter data parameters from treatment groups were comparable with the controls.
There were no external, visceral, or craniofacialabnormalities considered to be of toxicological relevance in any of the dose groups. Statistical analysis of data revealed no significant differences compared to the control group.
Skeletal examination of the Alcian blue and Alizarin red stained
foetuses revealed a range of findings which occurred at an incidence
generally comparable to or slightly lower or higher in the dose groups
when compared to the control group. Most of the skeletal findings
observed in HD group were within the historical control data range.
At the high dose when compared to the concurrent control group,
slightly higher litter incidences, but without achieving statistical
significance were noted for: incomplete ossification of frontal (B) (25%
compared to 15% in controls), interparietal (85% compared to 65% in
controls), parietal (B) (55% compared to 30% in controls), squamosal (B
and R) (15-25% compared to 0-5% in controls), zygomatic arch (B) (15%
compared to 5% in controls), femur (B) (15% compared to 5% in controls),
basioccipital with small hole (15% compared to 5% in controls), scapula
bent (B) (5% compared to 0% in control), scapula bent (R) (20% compared
to 0% in control), branched xiphoid cartilage (65% compared to 55% in
control), left 14th rudimentary rib (65% compared to 50% in control),
wavy ribs (65% compared to 55% in controls), rudimentary 7th cervical
rib (5-15% compared to 0% in control) misshapen humerus (20% compared to
5% in controls), unossified forelimb metacarpals (55% compared to 30% in
controls) and pelvic girdle (B) caudal shift (20% compared to 10% in
control). The observed reduced ossification without achieving
statistical significance of few bones at 1000 mg/kg bw/day that normally
exhibit rapid ossification during the last days of gestation indicates a
slight generalised skeletal delay at 1000 mg/kg bw/day. Generally
slightly delayed ossification is not regarded to persist postnatally and
not associated with long-term consequences on survival, general growth
and development and therefore is not considered to be adverse.
Rudimentary/short ribs are considered as transient abnormalities. In
contrast, full/long ribs are considered permanent and may cause health
effects in humans; however, postnatal consequences in rats are unknown
but are assumed to be minimal. This finding was not considered to be
treatment-related but spontaneous in nature. Wavy ribs and bent scapulae
are common findings in rodent studies and are considered to be
postnatally reversible. Thus, wavy ribs are classified as variations and
were not considered as an adverse effect of the treatment with the test
item.
No effects of ureidopropyltrialkoxysilane, mixed methoxy and ethoxy esters on females and foetuses were found at dose levels up to 1000 mg/kg bw/day. The NOAEL for maternal toxicity and embryo-foetal toxicity of the test substance in this study is considered to be =1000 mg/kg bw/day.
Justification for classification or non-classification
The available data on developmental toxicity of the registered substance do not meet the criteria for classification according to Regulation (EC) No 1272/2008. However, as no study is available to address fertility, the overall conclusion for classification of reproductive toxicity is data lacking.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.